Get the Stockscreener App
3.21
1.23%
-0.04
Liminatus Pharma Inc Stock (LIMN) Forecast
The Liminatus Pharma Inc (LIMN) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $547.71, representing a +16,963% increase from the current price of $3.21. The highest analyst price target is $986.28, and the lowest is $109.14.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month LIMN Price Target
Average 676.08
(+20,962% Upside)
Is Liminatus Pharma Inc (LIMN) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 35.55 | Neutral |
| STOCH(9,6) | 9.1708 | Buy |
| STOCHRSI(14) | 26.73 | Neutral |
| MACD(12,26) | -0.2275 | Sell |
| ADX(14) | 10.70 | Neutral |
| William %R | -100.00 | Buy |
| CCI(14) | -134.46 | Sell |
Buy: 2
Sell: 2
Neutral: 3
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
3.624
Sell
|
3.5388
Sell
|
| MA20 |
3.7748
Sell
|
3.7051
Sell
|
| MA50 |
4.3181
Sell
|
4.3444
Sell
|
| MA100 |
5.3238
Sell
|
8.593
Sell
|
| MA200 |
12.93
Sell
|
45.46
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, LIMN could be considered a Strong Sell, with 17 technical analysis indicators signaling 2 Buy signals, 12 signaling Sell signals and 3 Neutral signals. This might not be a good time to consider opening new positions on LIMN, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 35.55 indicates that LIMN is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 9.1708 indicates that LIMN is oversold. This indicates that LIMN price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 26.73 indicates that LIMN is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 10.7 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -134.46 indicates that LIMN is oversold. This means that the price has moved significantly lower than its average, indicating a potential buying opportunity.
Long-term LIMN price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Liminatus Pharma Inc financial reports and earnings history, Liminatus Pharma Inc (LIMN) stock could reach $708.25 by 2030, $2,552.06 by 2040 and $4,083.29 by 2050. See the projected annual prices until 2050 of the Liminatus Pharma Inc stock below:
- Liminatus Pharma Inc (LIMN) is expected to reach an average price of $1,560.64 in 2035, with a high prediction of $1,808.49 and a low estimate of $1,473.98. This indicates an $48,518% rise from the last recorded price of $3.21.
- Liminatus Pharma Inc (LIMN) stock is projected to chart a bullish course in 2040, with an average price target of $2,505.92, representing an $77,966% surge from its current level. The forecast ranges from a conservative $2,514.42 to a sky-high $2,552.06.
- Our analysts predict Liminatus Pharma Inc (LIMN) to jump 103.19K% by 2045, soaring from $3,315.68 to an average price of $3,315.68, potentially reaching $3,361.71. While $3,315.68 is the low estimate, the potential upside is significant.
- Liminatus Pharma Inc (LIMN) stock is expected to climb by 2050, reaching an average of $3,853.42, a $119.94K% jump from its current level. However, a wide range of estimates exists, with high and low targets of $4,083.29 and $3,855.92, respectively, highlighting the market's uncertainty.
Liminatus Pharma Inc Stock (LIMN) Year by Year Forecast
Liminatus Pharma Inc Stock (LIMN) Price Forecast for 2026
The predicted value for Liminatus Pharma Inc (LIMN) in 2026 is set at an average of $673.57. Estimates vary from a peak of $1,343.89 to a trough of $3.25, indicating an +20,884% surge from the present price of $3.21.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| November, 2026 | $378.09 | $109.14 | $986.28 | +11,678% |
| December, 2026 | $6.3122 | $73.69 | $1,343.89 | +96.64% |
Liminatus Pharma Inc Stock (LIMN) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Liminatus Pharma Inc (LIMN) is $97.89, with a high forecast of $187.51 and a low forecast of $8.2692. This indicates an +2,950% increase from the last price of $3.21.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $12.46 | $8.2692 | $151.42 | +288.25% |
| February, 2027 | $156.24 | $94.66 | $111.75 | +4,767% |
| March, 2027 | $186.71 | $153.93 | $187.51 | +5,716% |
| April, 2027 | $190.98 | $185.90 | $183.48 | +5,850% |
| May, 2027 | $179.45 | $187.87 | $178.45 | +5,490% |
| June, 2027 | $181.87 | $180.39 | $176.66 | +5,566% |
| July, 2027 | $158.55 | $160.23 | $175.92 | +4,839% |
| August, 2027 | $164.02 | $157.03 | $161.34 | +5,010% |
| September, 2027 | $147.65 | $148.63 | $157.43 | +4,500% |
| October, 2027 | $131.65 | $132.27 | $142.94 | +4,001% |
| November, 2027 | $109.35 | $109.57 | $124.50 | +3,307% |
| December, 2027 | $95.15 | $95.47 | $104.88 | +2,864% |
Liminatus Pharma Inc Stock (LIMN) Price Forecast for 2028
In 2028, Liminatus Pharma Inc (LIMN) is projected to reach an average price of $504.53, with a high projection of $1,004.79 and a low estimate of $4.2779. This indicates an +15,618% rise from the last price of $3.21.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $73.61 | $75.92 | $90.51 | +2,193% |
| February, 2028 | $58.36 | $58.59 | $68.47 | +1,718% |
| March, 2028 | $42.05 | $42.05 | $52.85 | +1,210% |
| April, 2028 | $25.58 | $25.77 | $37.72 | +696.85% |
| May, 2028 | $4.2779 | $4.2779 | $20.41 | +33.27% |
| June, 2028 | $441.16 | $442.39 | $385.63 | +13,643% |
| July, 2028 | $112.10 | $100.33 | $1,004.79 | +3,392% |
| August, 2028 | $199.65 | $223.99 | $298.89 | +6,120% |
| September, 2028 | $400.70 | $321.54 | $358.20 | +12,383% |
| October, 2028 | $494.64 | $441.36 | $458.64 | +15,309% |
| November, 2028 | $452.69 | $451.80 | $462.03 | +14,002% |
| December, 2028 | $430.49 | $432.24 | $439.58 | +13,311% |
Liminatus Pharma Inc Stock (LIMN) Price Forecast for 2029
The 2029 price forecast for Liminatus Pharma Inc Stock (LIMN) is $223.50 on average, with a high prediction of $418.38 and a low estimate of $28.63. This represents an +6,863% increase from the previous price of $3.21.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $403.24 | $404.15 | $418.38 | +12,462% |
| February, 2029 | $379.19 | $379.73 | $393.31 | +11,713% |
| March, 2029 | $349.27 | $349.78 | $355.62 | +10,781% |
| April, 2029 | $322.11 | $323.22 | $336.81 | +9,934% |
| May, 2029 | $290.67 | $290.68 | $311.60 | +8,955% |
| June, 2029 | $254.91 | $255.32 | $281.31 | +7,841% |
| July, 2029 | $213.28 | $215.15 | $245.56 | +6,544% |
| August, 2029 | $181.34 | $181.77 | $203.54 | +5,549% |
| September, 2029 | $147.13 | $147.55 | $172.82 | +4,484% |
| October, 2029 | $102.79 | $104.80 | $134.44 | +3,102% |
| November, 2029 | $71.63 | $71.92 | $93.71 | +2,132% |
| December, 2029 | $28.38 | $28.63 | $62.93 | +784.13% |
Liminatus Pharma Inc Stock (LIMN) Price Forecast for 2030
Liminatus Pharma Inc Stock (LIMN) is expected to reach an average price of $379.03 in 2030, with a high forecast of $746.26 and a low forecast of $11.81. This signifies an +11,708% surge from the last price of $3.21.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $772.33 | $11.81 | $708.25 | +23,960% |
| February, 2030 | $322.16 | $503.16 | $746.26 | +9,936% |
| March, 2030 | $540.48 | $443.74 | $665.68 | +16,737% |
| April, 2030 | $630.39 | $634.39 | $620.77 | +19,538% |
| May, 2030 | $739.71 | $703.97 | $695.22 | +22,944% |
| June, 2030 | $751.04 | $728.80 | $737.46 | +23,297% |
| July, 2030 | $696.95 | $703.45 | $725.12 | +21,612% |
| August, 2030 | $671.33 | $669.19 | $663.11 | +20,814% |
| September, 2030 | $610.32 | $610.73 | $641.35 | +18,913% |
| October, 2030 | $552.55 | $554.23 | $595.76 | +17,113% |
| November, 2030 | $520.53 | $521.80 | $538.19 | +16,116% |
| December, 2030 | $464.14 | $465.12 | $512.28 | +14,359% |
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):